To include your compound in the COVID-19 Resource Center, submit it here.

Tecemotide: Development discontinued

Merck's Merck Serono S.A. division discontinued development of tecemotide as monotherapy to treat NSCLC after the pharma reported last month that tecemotide missed the primary endpoint of improving OS vs. placebo in

Read the full 322 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE